|
**Overview**: **Biofire Pneumonia Plus Profile****Introduction**: The Biofire Pneumonia Plus Profile is a diagnostic tool designed to detect pneumonia pathogens using sputum or bronchoalveolar lavage (BAL) samples. Associated with conditions like bacterial pneumonia and viral respiratory infections, these disorders present with cough, fever, and severe complications if untreated, particularly in individuals with respiratory symptoms. Per the 2023 Bacteriology, Virology, and Mycology guidelines, the test employs PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for respiratory infection screening in clinical settings. This diagnostic falls under respiratory infection screening and targets individuals with suspected pneumonia, addressing the challenge of accurate pathogen assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its sputum/BAL-based approach ensures reliable detection.**Other Names**: Biofire Pneumo Pfl.**FDA Status**: FDA approved, CLIA certified for bacteriology, virology, and mycology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by microbiology labs, this test advanced pneumonia pathogen detection.**Purpose**: The test screens for 34 parameters including Streptococcus pneumoniae to guide pneumonia assessment, assess pathogen and resistance presence, and inform treatment and prevention strategies.**Test Parameters**: 1. Streptococcus pneumoniae, 2. Haemophilus influenzae, 3. Moraxella catarrhalis, 4. Staphylococcus aureus, 5. Klebsiella pneumoniae, 6. Pseudomonas aeruginosa, 7. Acinetobacter baumannii, 8. Escherichia coli, 9. Enterobacter cloacae, 10. Serratia marcescens, 11. Legionella pneumophila, 12. Mycoplasma pneumoniae, 13. Chlamydia pneumoniae, 14. Influenza A, 15. Influenza B, 16. Parainfluenza Virus, 17. Respiratory Syncytial Virus, 18. Rhinovirus, 19. Adenovirus, 20. Human Metapneumovirus, 21. Enterovirus, 22. Coronavirus, 23. Candida albicans, 24. Candida glabrata, 25. Candida parapsilosis, 26. Candida krusei, 27. Candida tropicalis, 28. Aspergillus fumigatus, 29. Antibiotic Resistance Gene (mecA), 30. Antibiotic Resistance Gene (blaKPC), 31. Antibiotic Resistance Gene (blaNDM), 32. Antibiotic Resistance Gene (blaVIM), 33. Antibiotic Resistance Gene (blaOXA), 34. Antibiotic Resistance Gene (blaIMP).**Pretest Condition**: No fasting required; patients should report cough, fever, or recent respiratory symptoms.**Specimen**: 2 mL sputum or BAL in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 1 month at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cough, fever, prior respiratory infections, or family history of infectious diseases, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated pneumonia including respiratory failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible pneumonia, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early infection stages.**Specialist Consultation**: General practitioners or specialists in pulmonology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Chest X-ray or culture for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Bacteriology, Virology, and Mycology Guidelines 2023, Journal of Infectious Diseases 2024, Microbiology 2025. |
